Analysts expect Curis, Inc. (NASDAQ:CRIS) to report $2.38 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Curis’ earnings, with estimates ranging from $2.26 million to $2.50 million. Curis reported sales of $2.44 million during the same quarter last year, which indicates a negative year over year growth rate of 2.5%. The business is scheduled to issue its next quarterly earnings results on Tuesday, November 6th.

According to Zacks, analysts expect that Curis will report full year sales of $9.89 million for the current year, with estimates ranging from $9.38 million to $10.40 million. For the next year, analysts forecast that the company will post sales of $10.79 million per share, with estimates ranging from $9.48 million to $12.10 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Curis.

Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.15. Curis had a negative net margin of 407.29% and a negative return on equity of 225.77%. The company had revenue of $2.36 million during the quarter, compared to the consensus estimate of $2.41 million.

Several brokerages have recently issued reports on CRIS. Zacks Investment Research downgraded shares of Curis from a “buy” rating to a “hold” rating in a research report on Monday, August 13th. Cowen reissued a “buy” rating on shares of Curis in a research report on Monday, August 6th. SunTrust Banks lowered their price objective on shares of Curis to $8.00 and set a “buy” rating for the company in a research report on Friday, August 3rd. Finally, ValuEngine downgraded shares of Curis from a “buy” rating to a “hold” rating in a research report on Monday, July 2nd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Curis has a consensus rating of “Buy” and a consensus target price of $18.75.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Arnhold LLC acquired a new position in Curis during the first quarter worth $1,907,000. GSA Capital Partners LLP boosted its holdings in Curis by 104.2% during the first quarter. GSA Capital Partners LLP now owns 1,913,208 shares of the biotechnology company’s stock worth $1,250,000 after purchasing an additional 976,151 shares during the last quarter. Sio Capital Management LLC acquired a new position in Curis during the first quarter worth $545,000. Candriam Luxembourg S.C.A. acquired a new position in Curis during the first quarter worth $523,000. Finally, Millennium Management LLC acquired a new position in Curis during the second quarter worth $540,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

Shares of CRIS stock traded up $0.02 during trading hours on Friday, hitting $1.62. 199,200 shares of the company were exchanged, compared to its average volume of 381,298. The company has a quick ratio of 3.01, a current ratio of 3.01 and a debt-to-equity ratio of 4.43. Curis has a 52 week low of $1.36 and a 52 week high of $9.40. The company has a market capitalization of $49.77 million, a price-to-earnings ratio of -0.90 and a beta of 1.13.

Curis Company Profile

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

See Also: What is a Fiduciary?

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.